Loading…
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis
Background The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study...
Saved in:
| Published in: | Prostate cancer and prostatic diseases 2020-06, Vol.23 (2), p.220-231 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3 |
| container_end_page | 231 |
| container_issue | 2 |
| container_start_page | 220 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 23 |
| creator | Guan, Yupeng Xiong, Haiyun Feng, Yupeng Liao, Guolong Tong, Tongyu Pang, Jun |
| description | Background
The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR.
Methods
Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS).
Results
A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85,
P
|
| doi_str_mv | 10.1038/s41391-020-0209-3 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2352657549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A624441332</galeid><sourcerecordid>A624441332</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3</originalsourceid><addsrcrecordid>eNp1kluL1TAQx4so7rr6AXyRgCC-ZM2t7alvy-INFgTR5zJNp-dkaZOapMrxq_plnO5ZXVdWQkiY-f0nmUtRPJXiVAq9eZWM1I3kQol1N1zfK46lqSteVmJzn-66Knm9KdVR8SilSyFEIxvxsDjSSmijGnNc_PyE3xBG57cs75DNMWx9SNlZNoLvk4UZWRiYxyXHMO_cyHPg436ad8HuM7II2QVGKJtHyDhivhNwnk2YIWVYQ1u6XNk9j5gcWX1en17dSF5vMbKZAPQ5sRyRzD377vKOQedIiTF4-ldk6H_AuGSYXI-vGVw9wsHDuKewj4sHA4wJn1yfJ8WXt28-n7_nFx_ffTg_u-DW1CJzqEWplFHSYt0Z0Vi5Qdl00lrZ9dCT0_aNMIMAoXtdk3WQ0A0KoNTK1qBPipeHuJTC1wVTbieXLI5UQQxLapUuVVXWpWkIff4PehmWSP8lyghTqUrU4obawoit80Ogctk1aHtWKWOo7VoRdXoHRavHyVkq0ODIfkvw4i_BjtqedylQ-agR6TYoD6ClnqSIQztHN0Hct1K06-S1h8lraerW3bSaNM-uM1u6Cfs_it-jRoA6AIlcfovxJvX_R_0FvFTogA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404626070</pqid></control><display><type>article</type><title>Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis</title><source>Springer Link</source><creator>Guan, Yupeng ; Xiong, Haiyun ; Feng, Yupeng ; Liao, Guolong ; Tong, Tongyu ; Pang, Jun</creator><creatorcontrib>Guan, Yupeng ; Xiong, Haiyun ; Feng, Yupeng ; Liao, Guolong ; Tong, Tongyu ; Pang, Jun</creatorcontrib><description>Background
The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR.
Methods
Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS).
Results
A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85,
P
< 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27–1.72,
P
< 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16–1.98,
P
< 0.001) in mCRPC patients treated with abiraterone.
Conclusions
NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/s41391-020-0209-3</identifier><identifier>PMID: 32034294</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/589/466 ; 692/53/2422 ; Analysis ; Androstenes - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers ; Biomarkers, Tumor - analysis ; Biomedical and Life Sciences ; Biomedicine ; Blood Platelets - pathology ; Cancer ; Cancer patients ; Cancer Research ; Care and treatment ; Castration ; Clinical trials ; Confidence intervals ; Development and progression ; Humans ; Indicators ; Inflammation ; Lymphocytes ; Lymphocytes - pathology ; Male ; Medical prognosis ; Meta-analysis ; Metastases ; Metastasis ; Neutrophils ; Neutrophils - pathology ; Oncology, Experimental ; Phenylthiohydantoin - administration & dosage ; Phenylthiohydantoin - analogs & derivatives ; Platelets ; Prognosis ; Prostate cancer ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Prostatic Neoplasms, Castration-Resistant - pathology ; Quality assessment ; Review Article ; Search engines ; Survival</subject><ispartof>Prostate cancer and prostatic diseases, 2020-06, Vol.23 (2), p.220-231</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3</citedby><cites>FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32034294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guan, Yupeng</creatorcontrib><creatorcontrib>Xiong, Haiyun</creatorcontrib><creatorcontrib>Feng, Yupeng</creatorcontrib><creatorcontrib>Liao, Guolong</creatorcontrib><creatorcontrib>Tong, Tongyu</creatorcontrib><creatorcontrib>Pang, Jun</creatorcontrib><title>Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Background
The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR.
Methods
Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS).
Results
A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85,
P
< 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27–1.72,
P
< 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16–1.98,
P
< 0.001) in mCRPC patients treated with abiraterone.
Conclusions
NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.</description><subject>631/67/589/466</subject><subject>692/53/2422</subject><subject>Analysis</subject><subject>Androstenes - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood Platelets - pathology</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Castration</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Development and progression</subject><subject>Humans</subject><subject>Indicators</subject><subject>Inflammation</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neutrophils</subject><subject>Neutrophils - pathology</subject><subject>Oncology, Experimental</subject><subject>Phenylthiohydantoin - administration & dosage</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Platelets</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Quality assessment</subject><subject>Review Article</subject><subject>Search engines</subject><subject>Survival</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kluL1TAQx4so7rr6AXyRgCC-ZM2t7alvy-INFgTR5zJNp-dkaZOapMrxq_plnO5ZXVdWQkiY-f0nmUtRPJXiVAq9eZWM1I3kQol1N1zfK46lqSteVmJzn-66Knm9KdVR8SilSyFEIxvxsDjSSmijGnNc_PyE3xBG57cs75DNMWx9SNlZNoLvk4UZWRiYxyXHMO_cyHPg436ad8HuM7II2QVGKJtHyDhivhNwnk2YIWVYQ1u6XNk9j5gcWX1en17dSF5vMbKZAPQ5sRyRzD377vKOQedIiTF4-ldk6H_AuGSYXI-vGVw9wsHDuKewj4sHA4wJn1yfJ8WXt28-n7_nFx_ffTg_u-DW1CJzqEWplFHSYt0Z0Vi5Qdl00lrZ9dCT0_aNMIMAoXtdk3WQ0A0KoNTK1qBPipeHuJTC1wVTbieXLI5UQQxLapUuVVXWpWkIff4PehmWSP8lyghTqUrU4obawoit80Ogctk1aHtWKWOo7VoRdXoHRavHyVkq0ODIfkvw4i_BjtqedylQ-agR6TYoD6ClnqSIQztHN0Hct1K06-S1h8lraerW3bSaNM-uM1u6Cfs_it-jRoA6AIlcfovxJvX_R_0FvFTogA</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Guan, Yupeng</creator><creator>Xiong, Haiyun</creator><creator>Feng, Yupeng</creator><creator>Liao, Guolong</creator><creator>Tong, Tongyu</creator><creator>Pang, Jun</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200601</creationdate><title>Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis</title><author>Guan, Yupeng ; Xiong, Haiyun ; Feng, Yupeng ; Liao, Guolong ; Tong, Tongyu ; Pang, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/589/466</topic><topic>692/53/2422</topic><topic>Analysis</topic><topic>Androstenes - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood Platelets - pathology</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Castration</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Development and progression</topic><topic>Humans</topic><topic>Indicators</topic><topic>Inflammation</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neutrophils</topic><topic>Neutrophils - pathology</topic><topic>Oncology, Experimental</topic><topic>Phenylthiohydantoin - administration & dosage</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Platelets</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Quality assessment</topic><topic>Review Article</topic><topic>Search engines</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guan, Yupeng</creatorcontrib><creatorcontrib>Xiong, Haiyun</creatorcontrib><creatorcontrib>Feng, Yupeng</creatorcontrib><creatorcontrib>Liao, Guolong</creatorcontrib><creatorcontrib>Tong, Tongyu</creatorcontrib><creatorcontrib>Pang, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guan, Yupeng</au><au>Xiong, Haiyun</au><au>Feng, Yupeng</au><au>Liao, Guolong</au><au>Tong, Tongyu</au><au>Pang, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><stitle>Prostate Cancer Prostatic Dis</stitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>23</volume><issue>2</issue><spage>220</spage><epage>231</epage><pages>220-231</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Background
The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR.
Methods
Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS).
Results
A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85,
P
< 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27–1.72,
P
< 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16–1.98,
P
< 0.001) in mCRPC patients treated with abiraterone.
Conclusions
NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32034294</pmid><doi>10.1038/s41391-020-0209-3</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2020-06, Vol.23 (2), p.220-231 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2352657549 |
| source | Springer Link |
| subjects | 631/67/589/466 692/53/2422 Analysis Androstenes - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - analysis Biomedical and Life Sciences Biomedicine Blood Platelets - pathology Cancer Cancer patients Cancer Research Care and treatment Castration Clinical trials Confidence intervals Development and progression Humans Indicators Inflammation Lymphocytes Lymphocytes - pathology Male Medical prognosis Meta-analysis Metastases Metastasis Neutrophils Neutrophils - pathology Oncology, Experimental Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - analogs & derivatives Platelets Prognosis Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Quality assessment Review Article Search engines Survival |
| title | Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revealing%20the%20prognostic%20landscape%20of%20neutrophil-to-lymphocyte%20ratio%20and%20platelet-to-lymphocyte%20ratio%20in%20metastatic%20castration-resistant%20prostate%20cancer%20patients%20treated%20with%20abiraterone%20or%20enzalutamide:%20a%20meta-analysis&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Guan,%20Yupeng&rft.date=2020-06-01&rft.volume=23&rft.issue=2&rft.spage=220&rft.epage=231&rft.pages=220-231&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/s41391-020-0209-3&rft_dat=%3Cgale_proqu%3EA624441332%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-a70522421ce7b409c18e19b1cc1bdad052cd904f0a03d37c1bf1abf2aa532c7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2404626070&rft_id=info:pmid/32034294&rft_galeid=A624441332&rfr_iscdi=true |